company background image
ATH logo

Alterity Therapeutics CHIA:ATH Stock Report

Last Price

AU$0.006

Market Cap

AU$29.3m

7D

0%

1Y

-14.3%

Updated

22 Dec, 2024

Data

Company Financials +

Alterity Therapeutics Limited

CHIA:ATH Stock Report

Market Cap: AU$29.3m

ATH Stock Overview

Engages in the research and development of therapeutic drugs to treat Alzheimer’s disease, Huntington disease, Parkinson’s disease, and other neurological disorders in Australia. More details

ATH fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Risk Analysis

Shareholders have been substantially diluted in the past year

Earnings are forecast to decline by an average of 19.7% per year for the next 3 years

Highly volatile share price over the past 3 months compared to the Australian market

Does not have meaningful revenue (A$4M)

+ 2 more risks

My Notes

Capture your thoughts, links and company narrative

Alterity Therapeutics Limited Competitors

Noxopharm

ASX:NOX

AU$27.8m

Cynata Therapeutics

ASX:CYP

AU$36.1m

Amplia Therapeutics

ASX:ATX

AU$28.8m

Biotron

ASX:BIT

AU$15.3m

Price History & Performance

Summary of share price highs, lows and changes for Alterity Therapeutics
Historical stock prices
Current Share PriceAU$0.006
52 Week HighAU$0.0075
52 Week LowAU$0.002
Beta0.70
1 Month Change100.00%
3 Month Change100.00%
1 Year Change-14.29%
3 Year Change-71.43%
5 Year Change-77.78%
Change since IPO-96.67%

Recent News & Updates

Recent updates

Shareholder Returns

ATHAU BiotechsAU Market
7D0%0.1%-2.7%
1Y-14.3%3.1%6.5%

Return vs Industry: ATH underperformed the Australian Biotechs industry which returned 3.1% over the past year.

Return vs Market: ATH underperformed the Australian Market which returned 6.5% over the past year.

Price Volatility

Is ATH's price volatile compared to industry and market?
ATH volatility
ATH Average Weekly Movement39.3%
Biotechs Industry Average Movement9.8%
Market Average Movement8.0%
10% most volatile stocks in AU Market16.8%
10% least volatile stocks in AU Market3.1%

Stable Share Price: ATH's share price has been volatile over the past 3 months compared to the Australian market.

Volatility Over Time: ATH's weekly volatility has increased from 29% to 39% over the past year.

About the Company

FoundedEmployeesCEOWebsite
199710David Stamleralteritytherapeutics.com

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer’s disease, Huntington disease, Parkinson’s disease, and other neurological disorders in Australia. The company’s lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase I clinical trial for the treatment of Parkinson’s disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer’s disease.

Alterity Therapeutics Limited Fundamentals Summary

How do Alterity Therapeutics's earnings and revenue compare to its market cap?
ATH fundamental statistics
Market capAU$29.26m
Earnings (TTM)-AU$19.12m
Revenue (TTM)AU$4.02m

7.3x

P/S Ratio

-1.5x

P/E Ratio

Is ATH overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ATH income statement (TTM)
RevenueAU$4.02m
Cost of RevenueAU$214.30k
Gross ProfitAU$3.80m
Other ExpensesAU$22.93m
Earnings-AU$19.12m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.0036
Gross Margin94.67%
Net Profit Margin-475.79%
Debt/Equity Ratio0%

How did ATH perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 06:07
End of Day Share Price 2024/12/20 00:00
Earnings2024/06/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Alterity Therapeutics Limited is covered by 7 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
George ZavoicoB. Riley Securities, Inc.
Vernon BernardinoFBR Capital Markets & Co.
George ZavoicoH.C. Wainwright & Co.